| abstract |
The invention relates to macitentan or a pharmaceutically acceptable salt thereof, for use in the treatment of pulmonary hypertension, wherein macitentan is to be administered in combination with a compound having prostacyclin receptor (IP) agonist properties which is 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}- N -(methylsulfonyl) acetamide, or a pharmaceutically acceptable salt thereof. It also relates to 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}- N -(methylsulfonyl)acetamide, or a pharmaceutically acceptable salt thereof, for use in the treatment of pulmonary hypertension, wherein 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}- N -(methylsulfonyl)acetamide is to be administered in combination with macitentan, or a pharmaceutically acceptable salt thereof. |